CTRI/2018/05/014060已完成未知
A 12-Month, open label, multi-center study to evaluate the efficacy and safety of intravitreal injections of Ranibizumab 0.5mg on cystoids, spongy and mixed Optical Coherence Tomography patterns secondary to Diabetic Macular Oedema (DME).
ovartis Healthcare Pvt Ltd0 个研究点目标入组 30 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •Patients must be above 18 years of age having type 1 or type 2 diabetes mellitus. Decrease in vision specifically due to DME. Retinal thickness less than 300 micron and bilaterally fit cases.
排除标准
- •Active intraocular inflammation, any active infection, history of uveitis, ocular disorders, epiretinal membrane, uncontrolled glaucoma, neovascularization of the iris, evidence of vitreomacular traction, active proliferative diabetic retinopathy.
研究者
相似试验
招募中
4 期
A 12 month, open label, multi-center study to evaluate the efficacy and safety of intravitreal injections of ranibizumab 0.5 mg on Cystoid, Spongy & Mixed OCT patterns secondary to Diabetic Macular Edema (DME)CTRI/2014/02/004379Dr V Narendran300
进行中（未招募）
不适用
A 12-week, open label, multicentre study assessing the efficcay and of Donepezil in patients discontinuing treatment with Memantine monotherapyAlzheimer's diseaseEUCTR2004-004918-17-CZPfizer Inc100
进行中（未招募）
不适用
A 12-week, open label, multicentre study assessing the efficcay and of Donepezil in patients discontinuing treatment with Memantine monotherapyMedDRA version: 7Level: VTcClassification code 10012271Alzheimer's diseaseEUCTR2004-004918-17-DEPfizer Limited100
进行中（未招募）
不适用
A 12-week, open label, multicentre study assessing the efficcay and of Donepezil in patients discontinuing treatment with Memantine monotherapyMedDRA version: 7Level: VTcClassification code 10012271Alzheimer's diseaseEUCTR2004-004918-17-FIPfizer Inc.100
进行中（未招募）
1 期
A 12-week, open label, multicentre study assessing the efficcay and of Donepezil in patients discontinuing treatment with Memantine monotherapyEstudio abierto y multicéntrico de 12 semanas de duración para valorar la eficacia y seguridad de Donepezilo en pacientes tras suspender el tratamiento con Memantina en monoterapiaAlzheimer's diseaseEUCTR2004-004918-17-ESPfizer, S.A.100